Di Bartolomeo E, Santarone S, Bavaro P, Di Carlo P, Olioso P, Papalinetti G, Di Bartolomeo P. Once-daily intravenous busulfan as myeloablative, reduced-toxicity conditioning regimen: results in young and adult patients with hematological malignant and nonmalignant diseases. Hematol Meeting Rep [Internet]. 2009 Jun. 23 [cited 2024 Nov. 21];2(6). Available from: https://www.pagepress.org/journals/hmr/article/view/771